Integrating Network Pharmacology and Experimental Validation to Identifying Key Herbal Components and Targets for Liver Cancer

整合网络药理学和实验验证,以鉴定肝癌的关键草药成分和靶点

阅读:1

Abstract

BACKGROUND: Traditional Chinese medicines (TCMs) offer a comprehensive approach to managing malignant tumors. OBJECTIVES: The present study aims to predict the high-frequency herbs, core components, and core targets for liver cancer treatment through data mining and network pharmacology. METHODS: The "traditional Chinese Medicine - active components - target - disease" network was established using Cytoscape to identify core components. A protein-protein interaction (PPI) network was constructed using the STRING database, and Cytoscape was used for network topological analysis to identify the core targets. Subsequently, molecular docking was performed using AutoDock Vina and PyMOL to calculate binding energies of core components with core targets. Furthermore, in vitro experiments explored quercetin's impact on liver cancer cell migration, apoptosis, and protein expression. RESULTS: A total of 50 high-frequency drugs were selected. Among these, Atractylodes macrocephala koidz, Astragalus membranaceus, Scutellaria barbata, and Cremastra appendiculata were high-frequency drugs for invigorating qi and heat-clearing in liver cancer treatment. There were 226 common targets of herbal medicine for liver cancer treatment. Based on the degree value, beta-sitosterol, kaempferol, stigmasterol, and luteolin potentially represented core components. Eight key targets, including JUN, MAPK1, RELA, TNF, ESR1, IL-6, TP53, and FOS, were screened out, which were involved in 417 entries and 159 pathways. Molecular docking verified a strong binding affinity of the key compounds to the core targets. In vitro experiments showed that quercetin induced apoptosis and inhibited migration activity of HepG2 cells in a dose-dependent manner by affecting the expression levels of p-c-Jun/c-Jun and c-Fos proteins. CONCLUSIONS: This study provides a foundational basis for future clinical application of TCMs in liver cancer treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。